Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trialPedro M. Folegatti, Alexander Batten, Mustapha Bittaye et al.|The Lancet|2020Cited by 2.6k
Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced seraDaming Zhou, Gavin Screaton, Wanwisa Dejnirattisai et al.|Cell|2021Cited by 1.2k
Reduced neutralization of SARS-CoV-2 B.1.1.7 variant by convalescent and vaccine seraPiyada Supasa, Juthathip Mongkolsapaya, Daming Zhou et al.|Cell|2021Cited by 529
Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responsesJordan R. Barrett, Catherine Green, Sandra Belij‐Rammerstorfer et al.|Nature Medicine|2020Cited by 340